Opko Health Inc. (NASDAQ:OPK)’s share price gapped up prior to trading on Friday . The stock had previously closed at $2.81, but opened at $2.72. Opko Health shares last traded at $2.57, with a volume of 175561 shares trading hands.
Several equities analysts recently issued reports on OPK shares. Zacks Investment Research cut shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. ValuEngine upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Barrington Research reiterated a “buy” rating and issued a $5.00 target price on shares of Opko Health in a research note on Thursday, February 28th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Opko Health presently has an average rating of “Buy” and an average price target of $9.67.
The company has a current ratio of 1.10, a quick ratio of 0.96 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -10.28 and a beta of 1.88.
In related news, Vice Chairman Jane Ph D. Hsiao acquired 10,000 shares of Opko Health stock in a transaction on Thursday, January 31st. The stock was bought at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the transaction, the insider now owns 24,455,147 shares of the company’s stock, valued at approximately $194,662,970.12. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock in a transaction on Friday, December 28th. The shares were bought at an average price of $3.13 per share, with a total value of $313,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $9,605,816.63. The disclosure for this purchase can be found here. Insiders have acquired 1,198,000 shares of company stock valued at $3,460,380 over the last 90 days. 42.74% of the stock is currently owned by company insiders.
Several institutional investors have recently added to or reduced their stakes in OPK. Diversified Trust Co purchased a new stake in shares of Opko Health during the fourth quarter worth $30,000. FDx Advisors Inc. purchased a new stake in shares of Opko Health during the fourth quarter worth $33,000. Douglas Lane & Associates LLC purchased a new stake in shares of Opko Health during the fourth quarter worth $42,000. Kovack Advisors Inc. purchased a new stake in shares of Opko Health during the fourth quarter worth $48,000. Finally, Two Sigma Advisers LP purchased a new stake in shares of Opko Health during the fourth quarter worth $49,000. 22.57% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Opko Health (OPK) Shares Gap Up to $2.72” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://weekherald.com/2019/03/22/opko-health-opk-shares-gap-up-to-2-72.html.
About Opko Health (NASDAQ:OPK)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Further Reading: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.